Study of adding venetoclax to standard chemotherapy for pediatric AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of a targeted pill (venetoclax) with standard chemotherapy for children and young adults with acute myeloid leukemia (AML). The hope is that adding venetoclax will improve how well the chemo works and reduce the chance of the leukemia coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with acute myeloid leukemia (AML) or a related blood condition like myeloid sarcoma or certain myelodysplastic syndromes (MDS) with extra blasts (immature cells).
- Age: older than 28 days and younger than 22 years.
- No prior cancer treatment except for one dose of intrathecal therapy (chemotherapy into the spinal fluid), hydroxyurea, or low-dose cytarabine (a mild chemo).
- If female and of childbearing potential, must have a negative pregnancy test before joining.
- People who could become pregnant or father children must agree to use effective birth control during the study and for 6 months after treatment.
- Must be willing to give written consent (or have parents/legal guardians consent).
- Liver function must be good (a test called direct bilirubin must be within a certain limit).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called venetoclax in children and young adults whose acute myeloid leukemia (AML) has returned after treatment. The drug may help block cancer cell growth. The study also looks at safety and how well the drug works when given alone or with other treatments.
This trial tests a combination of two oral drugs (venetoclax and decitabine/cedazuridine) for children and teens whose acute myeloid leukemia (AML) has returned or not improved after prior treatment. The goal is to find a safe dose and see if the drugs can help shrink or control the leukemia.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests a combination of three drugs – venetoclax, cytarabine, and metformin – for adults with AML who cannot receive standard high-dose chemotherapy. It aims to see if this gentler mix can help control the leukemia with fewer side effects.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.